Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals (NASDAQ: CRNX) announced that Scott Struthers, Ph.D., Founder and CEO, will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Crinetics Pharmaceuticals (NASDAQ: CRNX) announced that Scott Struthers, Ph.D., Founder and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 13, 2026 at 9:45 a.m. Pacific Time.
The announcement notes an audio-only live webcast will be available and an archived webcast will be posted on the company’s Events & Presentations page at www.crinetics.com/events. Investors seeking 1×1 meetings should contact their conference representative.
Details
News Market Reaction – CRNX
On Dec 19, the first trading day after this news, CRNX closed 6.36% above the previous close.
Data tracked by StockTitan Argus for the Dec 19 session.
Key Figures
- Conference edition
- 44th Annual
- J.P. Morgan Healthcare Conference
- Presentation time
- 9:45 a.m. Pacific Time
- Scheduled January 13, 2026 conference session
Historical Context
-
First patient dosed in CALM-CAH Phase 3 atumelnant trial for CAH.
-
Inducement stock options and RSUs granted to nine new employees.
-
First patient dosed in BRAVESST2 Phase 1/2 trial of CRN09682.
-
First patient randomized in Phase 3 CAREFNDR trial of paltusotine.
-
Inducement options and RSUs granted to new non-executive employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 13, 2026 at 9:45 a.m. Pacific Time.
To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events.
If you are interested in arranging a 1×1 meeting with management, please contact your conference representative.
ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.